Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9622
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pennisi, G. | - |
dc.contributor.author | Enea, M. | - |
dc.contributor.author | Romero-Gomez, M. | - |
dc.contributor.author | Bugianesi, E. | - |
dc.contributor.author | Wai-Sun Wong, V. | - |
dc.contributor.author | Fracanzani, A. L. | - |
dc.contributor.author | de Ledinghen, V. | - |
dc.contributor.author | George, Jacob | - |
dc.contributor.author | Berzigotti, A. | - |
dc.contributor.author | Vigano, M. | - |
dc.contributor.author | Sebastiani, G. | - |
dc.contributor.author | Cannella, R. | - |
dc.contributor.author | Delamarre, A. | - |
dc.contributor.author | Di Maria, G. | - |
dc.contributor.author | Lange, N. F. | - |
dc.contributor.author | Tulone, A. | - |
dc.contributor.author | Di Marco, V. | - |
dc.contributor.author | Camma, C. | - |
dc.contributor.author | Petta, S. | - |
dc.date.accessioned | 2024-05-16T03:11:23Z | - |
dc.date.available | 2024-05-16T03:11:23Z | - |
dc.date.issued | 2024 | - |
dc.identifier.uri | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9622 | - |
dc.description.abstract | BACKGROUND AND AIMS: International regulatory agencies recommend testing drug therapy for patients with noncirrhotic high-risk metabolic dysfunction-associated steatohepatitis (MASH) because they are at risk of liver-related events (LRE). We aimed to compare the risk of LRE in patients with MASLD stratified for F2-F4 fibrosis and MASH. APPROACH AND RESULTS: Overall, 1938 consecutive patients with biopsy-proven MASLD were enrolled. High-risk MASH was defined as MASH with F2-F4 fibrosis. LSM was measured by transient elastography. LRE were recorded during follow-up. Cox multivariate models were used to assess the association between high-risk MASH or F2-F4 fibrosis without MASH, of LSM (>=8 or >=10 Kpa), and of AGILE 3+ with LRE. The diagnostic performance for the prediction of LRE was assessed using the area under the receiver operating characteristic curves. The observed 5-year actuarial rate of LRE was 0.4%, 0.2%, 5.1%, and 6.6% in patients with F0-F1 fibrosis without MASH, F0-F1 fibrosis with MASH, F2-F4 fibrosis without MASH, and high-risk MASH, respectively. At multivariate Cox regression analysis using F0-F1 fibrosis without MASH as a reference, both F2-F4 fibrosis without MASH [adjusted HR (aHR) 9.96] and high-risk MASH (aHR 10.14) were associated with LRE. In the 1074 patients with available LSM, LSM >= 10 kPa (aHR 6.31) or AGILE 3+ > 0.67 (aHR 27.45) independently predicted the development of LRE and had similarly acceptable 5-year area under the receiver operating characteristic to high-risk MASH and F2-F4 fibrosis (0.772, 0.818, 0.739, and 0.780, respectively). CONCLUSIONS: The risk of LRE is similar in patients with high-risk MASH and with F2-F4 fibrosis without MASH. The use of LSM >= 10 kPa or AGILE 3+ > 0.67 could be an accurate option to identify patients with MASLD worthy to be included in clinical trials. Copyright 2023 American Association for the Study of Liver Diseases. | - |
dc.subject | Liver Cirrhosis | - |
dc.subject | Liver | - |
dc.subject | Fatty Liver | - |
dc.subject | Elasticity Imaging Techniques | - |
dc.subject | Biopsy | - |
dc.title | Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria | - |
dc.type | Journal Article | - |
dc.identifier.doi | Storr Liver Centre | - |
dc.identifier.journaltitle | Hepatology | - |
dc.identifier.department | Hepatology 79(4):912-925, 2024 | - |
dc.contributor.wslhd | George, Jacob | - |
dc.identifier.pmid | 37796137 | - |
dc.identifier.facility | Westmead | - |
Appears in Collections: | Westmead Hospital 2019 - 2024 |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.